Ignite Creation Date:
2025-12-24 @ 12:36 PM
Ignite Modification Date:
2026-05-30 @ 7:39 PM
Study NCT ID:
NCT04354961
Status:
UNKNOWN
Last Update Posted:
2023-11-08
First Post:
2020-04-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
Sponsor:
Fujian Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-07
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2020-04-17
First Submit QC Date:
None
Study First Post Date:
2020-04-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-07
Last Update Post Date:
2023-11-08
Last Update Post Date Type:
ACTUAL